Hansa Biosciences’ Idefirix (imlifidase) has reduced patients’ antibodies to a level that allows dosing in patients with Duchenne muscular dystrophy (DMD) with Sarepta and Roche’s Elevidys ...

Spine BioPharma's Phase III MODEL trial assessing SB-01 for people with CLBP associated with DDD failed to achieve its primary goal.

In the Susvimo cohort, subjects maintained an average best-corrected visual acuity of 67.6 letters. Credit: Andrey Sayfutdinov / Shutterstock.com. Roche’s Genentech has reported new five-year data ...

The Phase Ib trial only showed two patients achieving partial response and three achieving stable disease. Image credit: mi_viri / Shutterstock Nuvectis Pharma is terminating development of NXP800 in ...